Results show that various classes of antidepressants exert improving effects on cognitive function across several cognitive domains .
Specifically , studies suggest that SSRIs , the SSRE tianeptine , the SNRI duloxetine , vortioxetine and other antidepressants such as bupropion and moclobemide may exert certain improving effects on cognitive function in depression , such as in learning and memory and executive function .
The few non-pharmacological studies conducted employing cognitive orientated treatments and cognitive remediation therapy show promising results for the improvement of cognitive impairment in depression .
Cognitive dysfunction is of clinical significance and exerts longst and ing implication on patients ׳ function .
Pharmacological and non-pharmacological treatments of cognitive dysfunction are emerging .
This review evaluates pharmacological and non-pharmacological treatments of cognitive impairment primarily in the domains of memory , attention , processing speed and executive function in clinical depression .
Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.
OBJECTIVE Return of functional ability is a central goal in the treatment of major depressive disorder . We conducted two trials with the same protocol that was design ed to assess functioning after 8 Weeks of treatment with duloxetine . METHODS The a priori primary outcome was improvement in the Hamilton Depression Rating Scale ( HAMD ) item 7 ( work/activities ) . Secondary outcomes included improvement in depressive symptoms assessed by the HAMD Maier subscale , and improvement in functioning assessed by the Sheehan Disability Scale ( SDS ) , and the Social Adaptation Self-evaluation Scale ( SASS ) .  Patients were r and omly assigned to duloxetine 60 mg/day ( Trial I , n = 257 ; Trial II , n = 261 ) or placebo ( Trial I , n = 127 ; Trial II , n = 131 ) . Changes from baseline were analyzed using a mixed-effects model repeated measures approach . RESULTS At Week 8 , duloxetine was superior to placebo in improving HAMD work/activities ( p < 0.001 ) in Trial II , but not Trial I ( p = 0.051 ) , and Maier scores ( p < 0.01 ) in both trials . At Week 12 , duloxetine was superior to placebo on improving SASS scores in both trials , and the SDS in Trial II . CONCLUSION Treatment with duloxetine was associated with significant improvement in depressive symptoms compared with placebo , but improvement in HAMD work/activities was inconsistent at 8 weeks
Results show that various classes of antidepressants exert improving effects on cognitive function across several cognitive domains .
Specifically , studies suggest that SSRIs , the SSRE tianeptine , the SNRI duloxetine , vortioxetine and other antidepressants such as bupropion and moclobemide may exert certain improving effects on cognitive function in depression , such as in learning and memory and executive function .
The few non-pharmacological studies conducted employing cognitive orientated treatments and cognitive remediation therapy show promising results for the improvement of cognitive impairment in depression .
Cognitive dysfunction is of clinical significance and exerts longst and ing implication on patients ׳ function .
Pharmacological and non-pharmacological treatments of cognitive dysfunction are emerging .
This review evaluates pharmacological and non-pharmacological treatments of cognitive impairment primarily in the domains of memory , attention , processing speed and executive function in clinical depression .